Back
Science

Study Identifies Distinct Protein Patterns in Long COVID Patients Months After Infection

Generated on: Last updated: 2 sources
View source

Study Identifies Distinct Blood Protein Patterns in Long COVID

A study published in the journal Communications Medicine has identified distinct patterns of inflammatory and neurological proteins in the blood of individuals with long COVID, distinguishing them from those who have recovered from COVID-19 and healthy individuals. The research, which analyzed samples collected 6 to 9 months after initial infection, also examined the effects of vaccination and subsequent reinfection.

The authors noted the study was exploratory and requires validation in larger cohorts.

Study Design and Methodology

The research was conducted by scientists in Australia and Norway, involving participants from a longitudinal cohort in Victoria, Australia.

  • Participant Groups: Participants were divided into three groups: healthy individuals with no prior SARS-CoV-2 infection, individuals who had recovered from COVID-19, and individuals with long COVID.
  • Sample Collection: Initial blood samples were collected 6 to 9 months after the participants' first SARS-CoV-2 infection and prior to vaccination. A subset of participants provided additional samples after receiving a third COVID-19 vaccine dose and after experiencing a breakthrough infection.
  • Protein Analysis: Researchers measured levels of 182 inflammatory and neurology-related proteins using a technique called multiplexed affinity proteomics.
  • Data Analysis: Machine learning analyses, including LASSO regression and Boruta feature selection, were used to identify candidate protein biomarkers. Linear mixed-effects models were employed to analyze changes in protein levels over time.
  • Ethical Approval: The study received ethical approval from institutional review boards, and all participants provided written informed consent.

Key Findings on Protein Differences

The analysis revealed specific protein signatures associated with each group.

Proteins Associated with Long COVID: Several proteins were identified as potential discriminators for long COVID. These included:

  • Interleukin-20 (IL-20), which was elevated in individuals with long COVID.
  • Macrophage chemoattractant protein-1 (MCP-1).
  • Neuroblastoma suppressor of tumorigenicity 1 (NBL1).
  • Additional proteins, including C-type lectin domain containing 10A (CLEC10A), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and hydroxyacylglutathione hydrolase (HAGH), were also found to differ between long COVID patients and healthy individuals.

Proteins Associated with Recovery: Individuals who had recovered from COVID-19 also showed protein differences compared to healthy individuals. Fibroblast growth factor 19 (FGF-19) and cystatin D (CST5) were associated with recovery status.

Findings on Vaccination and Reinfection

The study tracked immune responses following a booster vaccine dose and subsequent breakthrough infections.

  • Antibody Response to Vaccination: After a booster dose, all three participant groups developed strong antibody responses, with high levels of spike-specific IgG.
  • Antibody Response to Reinfection: Following a breakthrough infection, individuals with long COVID and those who had recovered exhibited lower spike-specific antibody levels compared to newly infected healthy individuals.
  • Changes in Protein Markers: Levels of some protein markers, including sirtuin 2 (SIRT2) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), decreased after reinfection compared to pre-vaccination levels.
  • Inflammatory Patterns: The inflammatory protein patterns observed after the initial SARS-CoV-2 infection were not replicated following a reinfection in individuals with long COVID.

The study reported that vaccination did not worsen inflammation in individuals with long COVID. Inflammatory protein levels in this group either stabilized or decreased following vaccination.

Study Context and Limitations

  • Background: Research estimates that 5% to 30% of people infected with SARS-CoV-2 continue to experience symptoms months later, a condition known as long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC).
  • Study Limitations: The authors described the study as small and exploratory. They stated that the findings require validation in larger, independent cohorts.
  • Research Implications: The findings contribute to the identification of candidate biomarkers that may aid in the diagnosis and classification of long COVID. The data also provide information on the immune response to vaccination and reinfection in affected individuals.